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Abstract
Background: Focal adhesion kinase (FAK) and Src are protein tyrosine kinases that physically and
functionally interact to facilitate cancer progression by regulating oncogenic processes such as cell
motility, survival, proliferation, invasiveness, and angiogenesis.
Method: To understand how FAK affects oncogenesis through the phosphorylation of cellular
substrates of Src, we analyzed the phosphorylation profile of a panel of Src substrates in parental
and v-Src-expressing FAK+/+ and FAK-/- mouse embryo fibroblasts, under conditions of
anchorage-dependent (adherent) and -independent (suspension) growth.
Results:  Total Src-induced cellular tyrosine phosphorylation as well as the number of
phosphotyrosyl substrates was higher in suspension versus adherent cultures. Although the total
level of Src-induced cellular phosphorylation was similar in FAK+/+ and FAK-/- backgrounds, the
phosphorylation of some substrates was influenced by FAK depending on adherence state.
Specifically, in the absence of FAK, Src induced higher phosphorylation of p190RhoGAP, paxillin
(poY118) and Crk irrespective of adhesion state, PKC-δ (poY311), connexin-43 (poY265) and
Sam68 only under adherent conditions, and p56Dok-2 (poY351) and p120catenin (poY228) only
under suspension conditions. In contrast, FAK enhanced the Src-induced phosphorylation of
vinculin (poY100 and poY1065) and p130CAS (poY410) irrespective of adherence state, p56Dok-
2 (poY351) and p120catenin (poY228) only under adherent conditions, and connexin-43 (poY265),
cortactin (poY421) and paxillin (poY31) only under suspension conditions. The Src-induced
phosphorylation of Eps8, PLC-γ1 and Shc (poY239/poY240) were not affected by either FAK or
adherence status. The enhanced anchorage-independent growth of FAK-/-[v-Src] cells was
selectively decreased by expression of paxillinY118F, but not by WT-paxillin, p120cateninY228F or
ShcY239/240F, identifying for the first time a role for paxillinpoY118  in Src-induced anchorage-
independent growth. Knockdown of FAK by siRNA in the human colon cancer lines HT-25 and
RKO, resulted in increased paxillinpoY118 levels under suspension conditions as well as increased
anchorage-independent growth, supporting the notion that FAK attenuates anchorage-
independent growth by suppressing adhesion-dependent phosphorylation of paxillinY118.
Conclusion: These data suggest that phosphorylation of Src substrates is a dynamic process,
influenced temporally and spatially by factors such as FAK and adhesion.
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Background
Autophosphorylation of the focal adhesion kinase, FAK,
at Y397 upon integrin-mediated activation produces an
SH2-mediated binding site for Src-family tyrosine kinases,
or alternatively, other signaling proteins such as phos-
phatidylinositol 3-kinase (PI3K), Shc, phospholipase-Cγ
or Grb7 [1,2]. Once bound, Src can phosphorylate FAK on
several residues including Y925 resulting in the further
activation of FAK tyrosine kinase activity [3] and in the
phosphorylation of many other cellular substrates. FAK
also encodes ligands for multiple protein docking
domains such as SH3, an N-terminal FERM domain that
facilitates association with integrins and growth factor
receptors, and a C-terminal domain that facilitates paxil-
lin/talin binding and focal adhesion targeting (reviewed
in ref. [1,4,5]). Indeed, the maximal tyrosine phosphor-
ylation of many cellular substrates, such as paxillin,
requires both Src and FAK activity [6]. Current thinking
suggests that the mutual activation of Src and FAK in
response to growth factors, chemotactic agents and cell
adhesion leads to activation of a number of downstream
pathways in a spatially and temporally controlled manner
[7].
Both FAK and Src have been implicated as playing major
roles in cancer progression, especially relating to meta-
static potential. For example, activation of Src-family
kinases has been reported in many primary cancers such
as those affecting the colon, GI tract, breast and brain
(reviewed in ref. [8]), and activated Src seems to play a
critical role in the recruitment of endothelial cells to sites
of tumor angiogenesis [9-11]. FAK protein and activation
levels are increased in many primary cancers and further
increased in metastatic lesions [12-23]. Moreover, the loss
of FAK activity or expression suppresses metastatic pro-
gression in tumor xenograft models, underlining an
important positive role for FAK in the development of
malignancy [24].
Paradoxically, there are a growing number of studies cor-
relating lower FAK levels with poorer patient survival
[25,26], suggesting that FAK may actually attenuate some
of the lethal parameters of cancer progression.
As FAK and Src interact physically and functionally, it was
expected that FAK-null cells would be defective for onco-
genic transformation by v-Src. Thus, it was surprising that
in the absence of FAK, v-Src could induce morphological
transformation, cell motility, cell polarity and Matrigel
invasiveness [27,28], and even enhance the frequency of
anchorage-independent growth 5- to 10-fold [27].
Indeed, a high-resolution one-dimensional anti-phos-
photyrosine analysis of FAK+/+ versus FAK-/- fibroblasts
expressing v-Src identified fewer than 10 varying sub-
strates. Although the full phosphorylation of some cellu-
lar substrates, such as Endophilin A2, requires both FAK
and Src [29], it is possible that such substrates are dispen-
sable for oncogenic transformation. A further complica-
tion is that phosphorylation of some substrates, such as
PI3K, varied only under conditions of anchorage inde-
pendence [30]. Indeed, we demonstrated that the superac-
tivation of PI3K was required and sufficient for the
enhanced v-Src-induced anchorage-independent growth
of FAK-/- fibroblasts [30].
Here, we analyze how FAK affects the phosphorylation of
a panel of known Src substrates under conditions of
anchorage-dependent and -independent growth. Whereas
the majority of substrate phosphorylations neither
required FAK for v-Src-induced phosphorylation nor were
enhanced in the presence of FAK, we identified a small
number of substrates whose phosphorylation was affected
by FAK and/or adherence state. These variations suggest
that FAK and integrins might play either positive or nega-
tive roles during the overall process of malignant progres-
sion.
Methods
Cell lines and growth conditions
FAK+/+ and FAK-/- mouse embryo fibroblasts (MEF) from
a p53-/- lineage [31] transduced with v-Src or empty vec-
tor containing puror gene [30] were maintained in Dul-
becco's modified Eagle's medium (DMEM) supplemented
with 10% heat-inactivated bovine serum (BS). For suspen-
sion growth, cells were plated onto bacterial culture plates
pre-coated with 1% agarose and then incubated in
DMEM/10% BS for 1 d before harvesting. Trypan blue
exclusion staining indicated <5% decrease in cell viability
under these conditions compared to anchorage-depend-
ent growth (data not shown). FAK knockdown in human
colon cancer cell lines was performed by transfecting dou-
ble-stranded 10 nM FAK siRNA [32] or GFP siRNA (5'-
GGAGCGCACCAUCUUCUUCUU-3') [33] with Lipo-
fectamine for 6 hours in media containing BS, followed by
two washes with PBS and continued incubation in com-
plete media. After two days, aliquots of the cells were
plated in soft agar for AIG assays, and after one more day
of incubation in culture, aliquots of the cells were ana-
lyzed by IB FAK, paxillin, paxillinpoY118 and GAPDH lev-
els.
Protein isolation
FAK+/+, FAK-/-, FAK+/+[v-Src] and FAK-/-[v-Src] cells
grown under adherent or suspension conditions were
rinsed with cold PBS and lysed in cold RIPA buffer (10
mM Tris-HCl, pH 7.4, 0.15 M NaCl, 5 mM EDTA, 8% glyc-
erol, 1% Triton X-100, 0.1% SDS and 0.5% sodium deox-
ycholate) supplemented with Complete Mini protease
inhibitor cocktail tablets (1 tablet/10 ml RIPA; Roche
Diagnostics, Alameda, CA) and phosphatase inhibitors (1BMC Cancer 2009, 9:12 http://www.biomedcentral.com/1471-2407/9/12
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mM sodium orthovanadate and 10 mM sodium fluoride)
for 30 min. After centrifuging at 16,000 × g for 15 min at
4°C to remove debris, protein concentrations were deter-
mined using Bradford dye-binding assay (Bio-Rad, Her-
cules, CA).
Immunoblotting (IB) analysis
RIPA lysates containing 60 μg of cell protein were boiled
in laemmli buffer for 3 min, separated using 4–15% gra-
dient SDS-polyacrylamide gels (BioRad), electrophoreti-
cally transferred on to PVDF membrane (Perkin-Elmer,
Wellesley, MA) in transfer buffer (25 mM Tris-base, 192
mM glycine and 20% methanol) and immunoblotted (IB)
with various antibodies (Ab), as previously described
[34]. Membranes were blocked for 1 h at room tempera-
ture with either 3% bovine serum albumin or 5% non-fat
dry milk; the choice of blocking agent was determined
empirically so as to minimize the appearance of non-spe-
cific protein bands while not diminishing the signal of the
Src substrate. The primary phospho-Abs used, described
in Table 1A, were purchased from Invitrogen/BioSource
(Carlsbad, CA), Cell Signaling Technology, Inc. (Danvers,
MA), Santa Cruz Biotechnology (Santa Cruz, CA) or BD
Biotechnology (San Jose, CA), with the exception of Ab to
FAK (Chemicon, Temecula, CA). The secondary Abs used
were horseradish peroxidase conjugated anti-rabbit, anti-
mouse or anti-goat IgG (Chemicon). After treating with
Lumi-Light chemiluminescence substrate (Roche), Ab
binding was imaged and quantified using GeneTools soft-
ware on a Chemi-Genius2 bioimaging system (Syngene,
Frederick, MD). If required, membranes were stripped and
reprobed as described previously [35]. Note that v-Src typ-
ically decreases actin 2-fold and increases GADPH 2-fold
[27,36] and thus, protein-loading normalization incorpo-
rated these variations.
Immunoprecipitation (IP) analysis
IP with various Abs (Table 1B) was carried out essentially
as described previously [30] using 1 μg of Ab per 100 μg
of protein lysates plus pre-washed Protein A/G PLUS aga-
rose (Santa Cruz). The IB step used mAb-4G10 (Upstate/
Millipore, Billerica, MA) at 1:5000 using secondary Ab
and signal quantification described above.
Stable transfection
Puromycin-resistant FAK+/+[v-Src] and FAK-/-[v-Src] cells
were transfected using Lipofectamine 2000 (Invitrogen)
with the expression plasmids, pEBG-ShcY239/240F (GST
tag; gift of Kodi Ravichandran, University of Virginia),
pFLAG2AB-cateninY228F (below) or pEGFP-
paxillinY118F (gift of Alan Horwitz, University of Vir-
ginia) together with the vector pTRE2-hygro (gift of
Andrei Bakin, Roswell Park Cancer Institute) used as a
hygromycin-selection marker. Colonies were selected in
DMEM containing 500 μg/ml hygromycin (Roche),
expanded, and then the expression of the exogenous pro-
teins was verified by Western blotting using Abs specific
for the epitope tags (GST, FLAG or GFP). The pFLAG2AB-
cateninY228F expression plasmid was generated by
amplifying the mouse catenin1AY228F  coding sequence
from pRc/RSV-mctn-1A/228F (gift of Albert Reynolds,
Vanderbilt University) and then subcloning into
pcDNA3-FLAG2AB vector (gift of Scott Weed, West Vir-
ginia University) cut with Kpn1 and EcoRI.
Anchorage-independent growth
Growth in soft agar was assayed in 60-mm dishes pre-
pared with a lower layer of 0.7% agar in DMEM/10% BS
overlaid with top agarose (0.4%)/DMEM/10% BS con-
taining 104 suspended cells. Cells were fed every 3 days
with fresh culture medium. 3 weeks after plating, colonies
were stained with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyl tetrazolium bromide (Sigma) and counted.
Clonogenic assay
Cell viability was analyzed by seeding 4 × 102 cells into
100-mm dishes and then counting colonies after 10 days
of culture. Colonies were fixed and stained using Diff-
Quik Stain Set (DADE EBHRING, Newark, DE) according
to manufacturer's instructions, and then counted in tripli-
cate.
Results and Discussion
Many studies have demonstrated physical and functional
interactions between FAK and Src in response to integrin-
and growth factor-mediated signals. However, most of the
studies linking FAK/Src complexes with cell motility, pro-
liferation and cell survival in cancer progression involve
adherent cell populations. Yet, many parameters of cancer
biology in vivo, especially metastasis, require anchorage-
independent proliferation. To elucidate the roles of adhe-
sion and/or FAK on Src-induced oncogenesis, we devel-
oped FAK+/+ or FAK-/- MEF expressing relatively similar
protein and activity levels of the v-Src oncogene (Fig. 1A).
As we reported previously [27], the relative level of v-Src
autophosphorylation (poY416) under adherent condi-
tions was consistently 2-fold higher in the FAK-/- back-
ground, and this correlated with a slightly higher overall
level of cellular phosphotyrosyl proteins compared to the
FAK+/+ background (Fig. 1B, left panel). Interestingly,
overall v-Src-induced tyrosine phosphorylation of cellular
substrates, as well as the total number of substrates, was
slightly higher in v-Src cells kept in suspension, irrespec-
tive of FAK content (Fig. 1B, right panel). This was not due
to relative increases in Src activation levels in the sus-
pended cells (Fig. 1A). Although the gross level of Src-
induced tyrosine phosphorylation is similar in the pres-
ence or absence of FAK, there are a small number of sub-
strates whose relative phosphorylation level is either
increased or decreased by FAK (Fig. 1B). Moreover, inBMC Cancer 2009, 9:12 http://www.biomedcentral.com/1471-2407/9/12
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Table 1: Antibodies used in this study
(A) Phospho-specific antibodies
Substrate poY location Mol mass (kDa) Co.; Cat. #a MM/RP/GPb
cortactin 421 80/85 BioS; 44–854 RP
paxillin 31 68 BioS; 44–720 RP
paxillin 118 68 BioS; 44–722 RP
Shc 239/240 46, 52, 66 BioS; 44–830 RP
PKC-δ 311 77 BioS; 44–950 RP
PLC-γ1 783 130 Bios; 44–696 RP
p56Dok-2 351 56, 58 CS; 3911 RP
CAS 410 130 CS; 4011 RP
connexin-43 265 43 SC; sc-17220 GP
p120catenin 228 120 BD; 612536 MM
vinculin 100 130 BioS; 44–1074G RP
vinculin 1065 130 BioS; 44–1078G RP
(B) Antibodies used for IP
Substrate Mol mass (kDa) Co.; Cat. #a MM/RPb
Sam68 68 SC; sc-333 RP
Annexin II (H-50) 36(90) SC; sc-9061 RP
p190Rho-GAP 190 BD; 610149 MM
Eps8 97 BD; 610143 MM
Crk (Crk II) 40 BD; 610035 MM
(C) Antibodies used for total substrate protein level
Substrate Mol mass (kDa) Co.; Cat. #a MM/RPb
cortactin 80/85 CS; 3502 RP
paxillin 68 BD; 610551 MM
Shc 46, 52, 66 CS; 2432 RP
PKC-δ 77 SC; sc-213 RP
PLC-γ1 130 CS; 2822 RP
p56Dok-2 56, 58 CS; 3914 RP
CAS 130 BD; 610271 MM
p120catenin 120 BD; 610133 MM
vinculin 130 Sigma; V-9131 MM
GAPDH 37 SC; sc-25778 RP
(D) Epitope-tag antibodies
Epitope tag Co.; Cat. #a MM/RPb
GST SC; sc-138 MM
FLAG Sigma; F3040 MM
GFP Invitrogen; A6455 RP
a BioS – BioSource; CS – Cell Signaling; SC – Santa Cruz; BD – BD Biosciences
b Abs: RP – Rabbit polyclonal; MM – Mouse monoclonal; GP – Goat polyclonal
* Abs to actinin (Sigma; A5044), CASpoY165 (CS; 4015), CASpoY249 (CS; 4014), p120cateninpoY96 (BD; 612534), p120cateninpoY280 (BD; 612538), ezrinpoY353 (CS; 3144) did 
not recognize appropriately-sized bands.BMC Cancer 2009, 9:12 http://www.biomedcentral.com/1471-2407/9/12
Page 5 of 14
(page number not for citation purposes)
adherent cells, there were more phosphorylated Src sub-
strates in the absence of FAK (stars), whereas in the sus-
pended cells, there were a roughly equal number of
substrates favored in the presence (arrows) or absence
(stars) of FAK. These data are consistent with the notion
that FAK modulates the ability of activated Src to associate
with and/or phosphorylate specific cellular substrates
[27].
The possibility that variations in substrate choice by v-Src
could be influenced by FAK and/or adhesion may have
consequences on specific parameters of oncogenic trans-
formation. For example, v-Src induces 5- to 10-fold higher
anchorage-independent growth (AIG) in the absence of
FAK, correlating with a concomitant increase in PI3K acti-
vation levels under AIG conditions [27,30]. However, we
showed previously that the twofold higher level of acti-
vated v-Src is not responsible for the enhanced AIG (eAIG)
in the FAK-/- background inasmuch as varying v-Src levels
only altered soft agar colony size [30]. In order to clarify
roles for FAK and adhesion in regulating v-Src-induced
phosphorylation of cellular substrates, FAK+/+, FAK-/-
MEFs and their v-Src transformed derivatives, FAK+/+[v-
Src] and FAK-/-[v-Src], were incubated in the presence of
serum under conditions of adherence versus suspension,
and then cell lysates were probed by IB for changes in the
phosphorylation status of known Src substrates. Thus, IBs
were probed with either phospho-specific substrate Abs
(Table 1A), or alternatively, substrate proteins were
immunoprecipitated and then analyzed by anti-PTyr IB
using MAb-4G10 (Table 1B). In all cases, the change in the
relative phosphorylation state of each substrate was nor-
malized to apo-protein levels as well as to GAPDH, used
as a loading control. One caveat is that GAPDH levels typ-
ically increase twofold in murine cells transformed with v-
Src [30,36], a finding consistent throughout the current
study, and this was factored into the final normalization.
Table 2 shows that only a minority of the Src substrates
studied were unaffected by FAK and/or adhesion. In fact,
only the phosphorylation signals of Eps8, PLC-γ1 (at
Y783), and Shc (at Y239/240) showed no change under
these variables (Fig. 2). The phosphorylation of cortactin
(at Y421) and paxillin (at Y31) was unaffected by FAK
only in adherent cultures, whereas the phosphorylation of
Sam68 and PKC-δ (at Y311) was unaffected by FAK only
in suspension cultures. Interestingly, we observed a v-Src-
induced increase in cortactin protein levels, and moreo-
ver, a slower-migrating form whose abundance was
increased even more in FAK-/-[v-Src] cells. The phosphor-
ylation of several Src substrates was enhanced by FAK,
irrespective of adherence state. These include vinculin (at
both the Y100 and Y1065 sites) and CAS. In contrast, the
phosphorylation of p190RhoGAP, paxillin (at Y118) and
Crk was favored in the absence of FAK, irrespective of
adherence state. Lastly, although v-Src induced annexin II
protein levels, the phosphorylation of annexin II seemed
to be inhibited by v-Src in the absence of FAK.
The phosphorylation of a set of Src substrates was influ-
enced by FAK depending on adhesion conditions. Specif-
ically, the connexin43poY265 signal was enhanced by FAK
in suspension cultures, yet attenuated by FAK in adherent
cultures (Table 2; Fig. 2). Conversely, the p120
cateninpoY228 (Fig. 3) and p56Dok-2poY351 signals (Fig. 2)
were enhanced by FAK in adherent cultures, yet attenu-
ated by FAK in suspension cultures. The Src-induced phos-
phorylation of Sam68 was enhanced in the absence of
FAK only in adherent cultures (Fig. 2). Lastly, the Src-
induced phosphorylation of paxillin at Y118 in the
absence of FAK is enhanced to an even greater extent in
suspension cultures (10- versus 4-fold, respectively; Fig.
FAK- and adhesion-effects on v-Src substrate choice Figure 1
FAK- and adhesion-effects on v-Src substrate choice. 
(A) FAK+/+[puro], FAK-/-[puro], FAK+/+[v-Src] and FAK-/-
[v-Src] cells grown in adherent or suspension conditions as 
described in Experimental Procedures were analyzed by IB 
for levels of total Src, SrcpoY416 autophosphorylation or 
GAPDH (as a loading control). [Note that the decrease in 
Src protein, SrcpoY416 and GAPDH levels in lane 2 (second 
from left) is not reproducible; relative Src activation levels in 
adherent FAK-/-[v-Src] cells are typically comparable to 
those in adherent FAK+/+[v-Src] cells]. (B) Anti-phosphoty-
rosine (MAb4G10) IB from equal protein loads of FAK+/
+[puro], FAK-/-[puro], FAK+/+[v-Src] and FAK-/-[v-Src] cell 
lysates. M, proteins markers in kDa. Decreased Src-induced 
tyrosine phosphorylation events in the absence of FAK are 
marked by arrows whereas increased tyrosine phosphoryla-
tion events in the absence of FAK are marked by asterisks. 
These data are typical of at least three independent experi-
ments. A GAPDH IB is shown below as a loading control.
FAK:    +/+       -/- +/+       -/- +/+        -/- +/+        -/-
v-Src v-Src
IB:    Src
SrcpoY416
GAPDH
Adherent                           Suspension
A
B FAK:      +/+   -/- +/+    -/- M         +/+    -/- +/+     -/-
v-Src v-Src
Adherent                             Suspension
* *
* *
*
*
*
* *
* * *
*
*
* *
* *
130
100
70
55
40
35
170
PTyr
GAPDHBMC Cancer 2009, 9:12 http://www.biomedcentral.com/1471-2407/9/12
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4). Taken together, our data indicate that the phosphor-
ylation of most of the well-documented Src substrates is
influenced by FAK and/or adhesion.
It is possible that the eAIG induced by v-Src in the absence
of FAK is mediated by the enhanced phosphorylation of
p120catenin or paxillin, Src substrates whose phosphor-
ylation was consistently increased in FAK-/-[v-Src] cells.
To address this, stable FAK+/+[v-Src] and FAK-/-[v-Src] cell
clones were produced that express p120cateninY228F or
paxillinY118F alleles. As a negative control, the cells were
transfected with ShcY239/240F, whose phosphorylation is
affected by neither FAK nor adherence status (Table 2).
Figs. 5A–C show the expression of these exogenous pro-
teins (probed for their epitope tags). As expected, the
expression of these non-phosphorylatable mutants sup-
pressed the levels of endogenous ShcpoY239/240,
p120cateninpoY228 or paxillinpoY118. This effect was appar-
ent in multiple cell clones, and, in FAK-/-[v-Src] cells tran-
siently co-transfected with paxillinpoY118  and pEGFP
(sorted for GFP-positive cells; data not shown), strongly
suggesting that the Y->F mutants function as dominant-
interfering alleles. We cannot rule out, however, that these
mutants also affected the phosphorylation of other resi-
dues on their endogenous counterparts. Importantly, the
ectopic expression of paxillinY118F, but not
p120cateninY228F or ShcY239/240F, selectively decreased the
enhanced AIG in FAK-null cells compared to those express-
FAK and adhesion modulate v-Src-induced phosphorylation of various Src substrates Figure 2
FAK and adhesion modulate v-Src-induced phosphorylation of various Src substrates. (A) Lysates from adherent 
cultures of FAK+/+[puro], FAK-/-[puro], FAK+/+[v-Src] and FAK-/-[v-Src] cells were probed either directly by IB for specific 
phosphorylated form(s) of the Src substrate proteins, total substrate protein levels or GAPDH, or probed for total phosphor-
ylated protein by immunoprecipitating with substrate-specific Ab followed by IB for phosphotyrosine using MAb4G10. (B) 
Same IB or IP/IB analysis as in panel A using lysates of suspension cultures. Each of these blots is typical of at least duplicate 
independent experiments.
FAK:         +/+          -/- +/+        -/-
v-Src
97
68
46 
52 
66 
FAK:         +/+          -/- +/+        -/-
v-Src
GAPDH
PLC-γ γ γ γ1 poY783
PLC-γ γ γ γ1
Cortactin poY421
Cortactin
p130 CAS poY410
p130 CAS
PKC-δ δ δ δ
PKC-δ δ δ δ poY311
Connexin43 poY265
p56Dok2 poY351
p56 Dok2
Vinculin poY100
Vinculin poY1065
Vinculin
Sam68 (poY)
Sam68
Crk (poY)
Crk
Eps8 (poY)
Eps8
Annexin II (poY)
Annexin II
p190Rho-GAP (poY)
p190Rho-GAP
Shc poY239/240
Shc
Adherent                                                         SuspensionBMC Cancer 2009, 9:12 http://www.biomedcentral.com/1471-2407/9/12
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ing FAK (Fig. 5, panels A-C). This was not due to changes
in cell survival based on the similar clonogenic frequen-
cies between FAK+/+ or FAK-/- v-Src clones expressing the
paxillinY118F allele (Fig. 5A, right middle panel). As a fur-
ther control, we showed that the stable expression of the
WT-paxillin allele (expressed as a GFP-paxillin fusion)
failed to alter eAIG in FAK-/-[v-Src] cells (Fig. 5A, bottom
right). This strongly suggests that the enhanced Src-
induced phosphorylation of paxillin at Y118 in the
absence of FAK plays a significant role in inducing
enhanced Src-mediated AIG. This contrasts with the find-
ing that Src-induced phosphorylation of p120catenin on
Y228, but not of Shc on Y239/240, was critical to Src-
induced anchorage-independent growth irrespective of
the FAK background (Fig. 5B &5C).
Given the artificial nature of our cell system, we sought to
determine whether the relationship between loss of FAK,
Table 2: Relative Phosphorylation Level of Src Substrates in FAK+/+[Src] vs. FAK-/-[Src] Cells
Adherent Suspension
v-Src Substrates Similar levela More in FAK+/+
[v-Src]
More in FAK-/-
[v-Src]
Similar level More in FAK+/+
[v-Src]
More in FAK-/-
[v-Src]
Vinculin (poY100) 5 – 6 7 – 8
p190RhoGAP (poY)* 1.5 – 2 1.5 – 2
Shc (poY239/poY240) Yes Yes
Sam68 (poY)* 2 Yes
PLC-γ1 (poY783) Yes Yes
PKC-δ (poY311) 2 Yes
Paxillin (poY118) 4 10
Paxillin (poY31) Yes 2 – 3
Eps8 (poY)*, b Yes Yes
p56 Dok-2 (poY351) 5 2
Crk (poY)* 2 2
Cortactin (poY421)c Yes 2
Connexin43 (poY265)d 22 – 3
p120Catenin (poY228) 2 2
p130 CAS (poY410) 2 2
Annexin II (poY)* Yes Yes [3]e
*blotting with mAb 4G10 anti-PTyr was used to ascertain the level of tyrosine phosphorylation after immunoprecipitation with substrate-specific 
Abs.
a statistically equal level of relative substrate phosphorylation between FAK+/+[Src] and FAK-/-[Src] cells, based on triplicate experiments. Relative 
phosphorylation for a given experiment is calculated as the phospho- substrate signal normalized to total substrate protein level, then normalized to 
loading control proteins. Note that Src transformation increases GAPDH protein levels ~2-fold and decreases actin protein level ~2-fold in the 
FAK+/+ background in adherent cells only.
b for both 97 kDa and 68 kDa Eps8 isoforms.
c in adherent cultures, the 80 kDa cortactin isoform protein level is reduced in the absence of FAK, but the relative phosphorylation levels are 
similar.
d connexin-43 (poY265) levels were not normalized.
e relative decrease in phospho-annexin II levels in suspended FAK-/-[v-Src] cells.BMC Cancer 2009, 9:12 http://www.biomedcentral.com/1471-2407/9/12
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increased paxillinpoY118 and eAIG was manifest in human
cancer cells lines. Colon cancer is marked by the activa-
tion of Src, mainly through overexpression although
small percentages encode mutated Src known to cause
upregulation of its intrinsic tyrosine kinase activity [37].
Because the knockdown of FAK in cancer cell lines using
antisense oligonucleotides or siRNAs often induces apop-
tosis [27,38-42], we screened a panel of human colon can-
cer cell lines for those that failed to apoptose after
treatment with FAK siRNA. Treatment of two such lines,
HT-25 and RKO, with FAK-siRNA under conditions of
adherent or suspension growth caused 3- to 4-fold
decreases in FAK protein level (Fig. 6A). The loss of FAK
marginally decreased cell survival as measured by clono-
genic colony growth (Fig. 6C), yet resulted in significant
increases in AIG as measured by soft agar colony-forming
frequencies (Fig. 6B). Note that the loss of FAK did not
affect the colony size formed by these cell lines (not
shown). If the AIG frequency is normalized to cell survival
rates, FAK knockdown induces an equivalent 1.75-fold
increase in relative AIG in both HT-25 and RKO over con-
trol cells (GFP siRNA). Given that the loss of FAK in these
cancer cell lines recapitulated the eAIG found in our FAK-
/-]v-Src] MEF, we analyzed how the loss of FAK affected
paxillinpoY118 levels under adherent or suspension condi-
tions. Suspension cells treated with siFAK exhibit
increased paxillinpoY118 levels, especially a fast-migrating
isoform, whereas the loss of FAK in adherent cells resulted
in decreased relative paxillinpoY118 levels (Fig. 6A). The
protein levels of GAPDH (Fig. 6A) or paxillin (not shown)
did not alter by these conditions. These data strengthen
the notion that in HT-25 and RKO, FAK may antagonize
AIG by inhibiting the phosphorylation of paxillinY118 by
activated Src-family kinases.
Cancer progression, especially metastasis, is controlled by
multiple stages, with varying dependencies on the prolif-
erative, motility and survival signals mediated by cell
adhesion and FAK [1,43]. For example, primary and met-
astatic site tumors cells require growth conditions less
dependent on integrin-mediated adhesion than individ-
ual metastatic cells require while intravasating from pri-
mary lesion and extravasating to peripheral sites [44].
Similarly, the motility-promoting activity of FAK would
be more desirable to facilitate extravasation and intravasa-
tion of metastatic cells [45], yet once at peripheral sites,
continued FAK motility signals would likely be sup-
pressed in the growing metastatic lesion. Although the
activation of Src-family kinases has been noted as an
important event in early cancer progression- mostly
involved in mediating proliferative signals- there is
mounting data that Src signaling is especially critical for
the metastatic process, specifically, to facilitate cancer cell
survival and neovascularization of metastatic sites
[8,9,11]. Our results indicate that in a majority of well-
documented Src substrates, Src-induced phosphorylation
is influenced by FAK and/or adhesion. Some are FAK
dependent whereas as others are attenuated by FAK, irre-
spective of adherence state. Yet others are affected by FAK
only under adherent or non-adherent conditions. Because
our cells were derived in a p53-/- background [31], it
would be interesting to understand how p53 might regu-
late these phosphorylations. However, the conditional
FAK and adhesion modulate v-Src-induced phosphorylation  of p120catenin Figure 3
FAK and adhesion modulate v-Src-induced phospho-
rylation of p120catenin. Lysates from adherent or suspen-
sion cultures of FAK+/+[puro], FAK-/-[puro], FAK+/+[v-Src] 
and FAK-/-[v-Src] cells were probed by IB for total 
p120catenin, p120cateninpoY228 or GAPDH. These data are 
typical of at least three independent experiments. Arrows, 
p120catenin identified by the p120cateninpoY228-specific Ab.
Enhanced v-Src-induced paxillin phosphorylation is attenu- ated by FAK Figure 4
Enhanced v-Src-induced paxillin phosphorylation is 
attenuated by FAK. Lysates from adherent or suspension 
cultures of FAK+/+[puro], FAK-/-[puro], FAK+/+[v-Src] and 
FAK-/-[v-Src] cells were probed by IB for total paxillin, 
paxillinpoY31, paxillinpoY118 or GAPDH. These data are typical 
of at least three independent experiments.
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Phosphorylation of paxillinpoY118 is required for enhanced AIG by FAK-/-[v-Src] cells Figure 5
Phosphorylation of paxillinpoY118 is required for enhanced AIG by FAK-/-[v-Src] cells. (A) Left panel- IB analysis of 
FAK+/+[v-Src] or FAK-/-[v-Src] cell clones ("cl.") stably transfected with empty vector (--) or a GFP-paxillinY118F-expressing 
vector, probed with Abs specific for GFP, paxillinpoY118 or GAPDH. Aliquots of these cells were analyzed by anchorage-inde-
pendent growth (top right) or for clonogenic efficiency (bottom right) as described in Materials and Methods. Error bars, S.E. *, 
P < 0.01. (B) A similar analysis as in panel A except on cells stably expressing FLAG-p120Y228F, with IBs probed for FLAG, 
p120cateninpoY228 or GAPDH. Note that there is no statistical difference in the p120cateninY228F-mediated decrease in AIG 
between the FAK+/+[v-Src] and FAK-/-[v-Src] cells. (C) A similar analysis as in panel A except on cells stably expressing GST-
ShcY239/240F, with IBs probed for GST-tag, ShcpoY239/240, or GAPDH.
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loss of FAK in v-Src-transformed p53+/+ MEF (Lingqiu
Gao and I.H. Gelman, unpublished data; Hilary Beggs,
UCSF, personal communication) or the ectopic expres-
sion of WT-p53 in our FAK-/-[v-Src] cells (Sanjay Sachdev
and I.H. Gelman, unpublished data) leads to rapid apop-
tosis, making this determination technically unfeasible at
the present time. In sum, our data strongly suggest that
FAK- and adhesion-signaling can modulate which sub-
strates are favored (or disfavored) by Src, thereby influenc-
ing the various dynamic biologies that contribute to
cancer progression.
In regards to mechanism, we speculated previously that
regulation of cytoskeletal dynamics by FAK and/or adhe-
sion-activated signals might affect co-localization of Src
with its potential substrates. Alternatively, even if FAK/Src
complexes are found at the subcellular sites of potential
substrates, such as focal adhesion plaques, the preferential
binding of FAK to the Src-SH2 domain through its
poY397 site may shift substrates to other, weaker binding
sites on Src, such as the SH3 domain, thereby resulting in
lower levels of phosphorylation [30].
Loss of FAK in human colon cancer cell lines leads to increased AIG and paxillinpoY188 accumulation under suspension growth  conditions Figure 6
Loss of FAK in human colon cancer cell lines leads to increased AIG and paxillinpoY188 accumulation under sus-
pension growth conditions. (A) IB analysis of HT-25 and RKO colon cancer cells grown under adherent or suspension con-
ditions that were incubated with either FAK or GFP siRNA for 72 h, probed for FAK, paxillin (not shown) paxillinpoY118 or 
GAPDH. Note that paxillin protein levels did not change under these conditions. Aliquots of the cells in panel A were analyzed 
for anchorage-independent growth (panel B) or for clonogenic efficiency (panel C) as described in Materials and Methods. 
Error bars, S.E. from triplicate plates in two independent experiments. p < 0.01. (D) Normalized AIG, based on the mean of 
the AIG data from panel B normalized to the mean of the survival data in panel C.
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There are very few studies that identify an obligate role for
FAK in enhancing Src-mediated phosphorylation of spe-
cific substrates. For example, Wu et al. [29] demonstrated
that full phosphorylation of endophilin A2 by Src requires
FAK. Brown et al. [46] show that Src and FAK cooperate to
phosphorylate PKL during cytoskeletal remodeling. El
Annabi et al. [47] describe a system in which insulin-
mediated receptor activation and IRS-1 tyrosine phospho-
rylation is enhanced in cells adhering to fibronectin versus
suspended cultures, and that phosphorylation can be
restored in suspended cells by the overexpression of both
FAK and Src. Ruest et al. [48] showed that maximal phos-
phorylation of p130CAS in COS-7 cells required co-
expression of Src and FAK. Roy et al. [28] showed that the
ability of v-Src to phosphorylate the FAK family member,
Pyk2, is attenuated by FAK, whereas the Src-induced phos-
phorylation of CAS and paxillin is enhanced by FAK. Hsia
et al. [49] and Moissoglu et al. [30] identify another exam-
ple where a potential Src substrate, STAT3, required nei-
ther FAK nor adhesion for maximal phosphorylation.
The current study is the first to describe either positive or
negative roles for FAK and adhesion in the Src-induced
phosphorylation of PKC-δ, p190RhoGAP, Shc, p120 cat-
enin, connexin-43, cortactin, p56Dok-2, Crk, Eps8, PLC-
γ1, Sam68 and vinculin. Our data indicate that FAK and/
or adhesion status affect the phosphorylation of most of
these substrates.
Phosphorylation of PKC-δ at Y311 by Src is associated
with caspase-mediated apoptosis in many cell types
(reviewed in ref. [50]). Our data showing increased PKC-
δY311  phosphorylation in adherent FAK-/-[v-Src] cells,
whereas phosphorylation in suspension cells is FAK-inde-
pendent, suggests that the ability of FAK to suppress apop-
tosis [1-4] is enhanced by integrin-mediated signals.
The Src-induced phosphorylation of Shc, PLC-γ1 and
Eps8 was unaffected by FAK or adherence state. Phospho-
rylation of PLC-γ1 at Y783 is specifically induced by
integrin-mediated adhesion, and mutation of this site
antagonizes adhesion [51]. However, Tyorogov et al. [52]
showed that adhesion-induced PLC-γ1poY783 could occur
in FAK-deficient MEF, in line with our findings that Src-
induced PLC-γ1poY783 is FAK-independent.
The Src-induced phosphorylation of p190RhoGAP and
Crk is enhanced slightly in the absence of FAK irrespective
of adherence state. Although p190RhoGAP can bind to
and be phosphorylated by FAK [53,54], our data indicate
that the v-Src-induced phosphorylation of p190RhoGAP
is not dependent on FAK or adhesion. p190RhoGAP
phosphorylation by v-Src is known to activate its ability to
suppress RhoA, thereby inhibiting the formation of actin
stress fibers and focal adhesion complexes in transformed
cells [55]. Moreover, v-Src facilitates increased complex
formation between p190RhoGAP and p120RasGAP.
In contrast, FAK may play a critical role in regulating
p190RhoGAP activity in untransformed cells. Specifically,
Y31/118-phosphorylated paxillin has been shown to lib-
erate p190RhoGAP from complexes with p120 RasGAP,
thereby allowing p190RhoGAP to suppress RhoA-medi-
ated cytoskeletal remodeling in endothelial cells [56].
Indeed, our current data show that the relative levels of
paxillinpoY31/118 are decreased in FAK-/- versus FAK+/+
MEF (i.e.- not expressing v-Src, Fig. 3), suggesting that FAK
is required for p190RhoGAP-mediated inhibition of
RhoA.
The Src-induced phosphorylation of p130CAS and vincu-
lin was enhanced by FAK but not by adherence state. For
example, phosphorylation of the Crk-associated substrate,
p130CAS, by v-Src was favored slightly in FAK-expressing
cells even though its ability to be phosphorylated at lower
levels by v-Src in adherent FAK-/- cells [27,28] may be the
result of adhesion-activated Pyk2 [57]. Our current
results, that Src-induced phosphorylation of CAS at Y410
in adherent culture is enhanced by FAK, are similar to
those of Roy et al. [28], though they looked at the overall
tyrosine phosphorylation of CAS. In regards to biologic
significance, the anchorage-independent tyrosine phos-
phorylation of CAS correlates with suppression of anoikis
[58]. Src-mediated tyrosine phosphorylation of CAS is
required for the invasive phenotype and metastasis forma-
tion but not for primary tumor growth [59]. Our present
observation of enhanced phosphorylation of CAS in the
presence of FAK, irrespective of adhesion, argues that FAK
may positively influence the ability of Src to suppress
anoikis and induce invasion and metastasis. Moreover,
Patwardhan et al. [60] observed that CAS, independent of
its phosphorylation status, enhances the ability of Src to
promote anchorage-independent growth. Thus, taken
with our data, we can conclude that differential CAS phos-
phorylation cannot be responsible for enhanced AIG we
detect in the absence of FAK.
The FAK-dependent enhancement of Src-induced vinculin
phosphorylation (at both Y100 and Y1065) irrespective of
adherence state conflicts somewhat with the previous find-
ings of Chang et al. [61] who showed that anoikis induced
by FAKY397F expression in v-Src-transformed MEF only cor-
related with decreased CAS, but not vinculin, talin or paxil-
lin protein levels. It should be stressed, though that the
FAKY397F allele is not equivalent to a FAK-null condition in
that i) FAK can bind v-Src (but not c-Src) through SH3-
mediated interactions [62], and ii) FAKY397F may facilitate
anoikis by acting as a sink for other survival factors.BMC Cancer 2009, 9:12 http://www.biomedcentral.com/1471-2407/9/12
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The ability of FAK to either enhance or attenuate Src-
induced phosphorylation of paxillin, p120catenin, con-
nexin and p56Dok-2 was influenced by adherence state.
We found that whereas Src-induced paxillinY118 phospho-
rylation is attenuated by FAK, FAK is required for optimal
phosphorylation of paxillinY31  in suspension cultures.
Interestingly, Roy et al. [28] and our lab [30] showed pre-
viously that the overall level of Src-induced paxillin tyro-
sine phosphorylation level is not affected by FAK, yet we
showed that FAK-/-[v-Src] cells lacked some of the super-
phosphorylated, slow-mobility paxillin isoforms found in
FAK+/+[v-Src] cells. Our current work makes use of the
site-specific phospho-Abs to show that FAK can either
induce or attenuate paxillin phosphorylation at specific
residues.
Our data show that FAK enhances Src-induced
p120cateninpoY228 in adherent cultures yet attenuates Src-
induced p120cateninpoY228 in suspension cultures. The
tyrosine phosphorylation of p120catenin is associated
with the loss of catenin-cadherin cell-cell adherens junc-
tions in several systems [63,64]. The preponderance of
data identifies functions for FAK in focal adhesion com-
plexes, and not in cell-cell junctions. Not surprisingly,
only one study indirectly links FAK with cell-cell junc-
tions: Irby and Yeatman [65] show that FRNK, a naturally-
occurring dominant-interfering FAK allele, can restore
some of the Src-suppressed cell-cell interactions. This sug-
gests that FAK functions downstream of Src to facilitate
catenin phosphorylation, a conclusion backed by our
findings. Nonetheless, p120cateninpoY228  levels do not
correlate with changes in cell-cell interactions under sus-
pension conditions with our MEF. How FAK might asso-
ciate with or antagonize the phosphorylation of catenins
in the absence of adherence signaling is unclear at this
time. One hint may come from the finding that
p120catenin translocates from cell-cell junctions to the
cytoplasm during epithelial to mesenchymal transition
and that cytoplasmic p120catenin correlates with poor
prognosis and lymph node metastasis in colon cancer
[66].
Phosphorylation of p56Dok-2 at Y351 establishes a bind-
ing site for the SH2 domain of adaptor protein Nck, which
is involved in the organization of actin cytoskeleton [67-
69]. Noguchi et al. [70] observed no appreciable differ-
ence between adherent versus suspension cultures of v-Src
transformed rat fibroblasts in regards to Dok-1 phospho-
rylation level. However, the current study is the first to
show that p56Dok-2 phosphorylation by Src is enhanced
by FAK in adherent cells but attenuated by FAK in suspen-
sion cells. The significance of our observation remains
unclear at this point but suggests that FAK can positively
or negatively influence actin cytoskeletal dynamics
through p56DOK-2 phosphorylation depending on
adherence state.
We previously demonstrated that the AIG induced by Src
in MEF was enhanced 5- to 10-fold in the absence of FAK
[27]. The phosphorylation of two Src substrates, paxillin
(at Y118), and p120catenin (at Y228), was increased in
suspended FAK-/-[v-Src] cells relative to cells expressing
FAK and growing in adherent conditions. Our data
strongly suggest that paxillinpoY118, but not
p120cateninpoY228, regulates the enhanced AIG phenome-
non. This is the first identification of a required role for a
specific paxillin phosphorylation event in AIG, and adds
to recent evidence correlating paxillin phosphorylation at
Y118 with AIG in colon cancer cells forced to express
β4GalNAc-T3 [71] and the requirement for paxillin for
epidermal growth factor-induced AIG growth of JB6 Cl41
fibroblasts [72]. A central role for paxillinpoY118 in driving
AIG is underlined by our finding that two human colon
cancer epithelial cell lines, HT25 and RKO, exhibit
increased AIG after siRNA-mediated FAK knockdown, cor-
relating with increased relative paxillinpoY118 levels under
suspension growth conditions.
We showed previously that PI3K/AKT is a major mediator
of Src-induced enhanced AIG in the absence of FAK [30].
Thus, FAK seems to attenuate the ability of Src to bind to
and/or phosphorylate paxillin at Y118 (this study) and
the p85 regulatory subunit of PI3K [30], resulting in
decreased AIG. It is unclear whether paxillin and PI3K
control common AIG-inducing pathways; the possibility
that there is crosstalk between these two mediators has
not been described in the literature to date.
Conclusion
Our data identify FAK- and/or adhesion-regulated effects
on the choice of substrates phosphorylated by Src. As
oncogenic transformation and progression are multi-step
processes, it will be interesting to determine how the FAK
and adhesion effects we identified might correlate with
the dynamic changes to the dependence on motility, cell
survival and adhesion required at different points of can-
cer progression.
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